With substantial support across the political spectrum, the Obama administration has included in the American Recovery and Reinvestment Act more than $1 billion to support comparative effectiveness research. At the same time, the president has demanded reforms in the US health care system to make health care more affordable for all US citizens. This Commentary focuses on the interaction of these 2 initiatives: what will be the cost effect of spending $1 billion on comparative effectiveness research?....
The remainder of this op-ed can be found at jama.ama-assn.org
This commentary originally appeared in The Journal of the American Medical Association on July 8, 2009. Commentary gives RAND researchers a platform to convey insights based on their professional expertise and often on their peer-reviewed research and analysis.